Doctors are wary of prescribing Lotronex as a therapy for irritable bowel syndrome (IBS) despite the drug’s significant advantages over current and emerging therapies, a new report has found.
The report by Decision Resources shows that doctors are reluctant to prescribe Lotronex because of side effects linked to constipation, which in rare cases have led to blood transfusion, hospitalisation, surgery and even death.
Go deeper with GlobalData
Surveyed primary care physicians said that the therapy’s effect on overall IBS symptoms is the attribute that most influences their prescribing decisions in non-constipation predominant IBS.
The report also identifies Tioga / Ono’s asimadoline as the leading non-constipation predominant irritable bowel syndrome treatment, following the launch of asimadoline in 2013.
Lotronex is indicated for women with severe IBS, whose main problem is diarrhoea and who have not been helped by other treatments.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
